Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BRISBANE, Calif., Aug. 11, 2017 -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that Cameron Durrant, MD, chairman and CEO, has been named a PharmaVOICE 100 Red Jacket Award honoree as part of the annual PharmaVOICE 100.
The PharmaVOICE 100 Red Jacket Award is a prestigious annual distinction that serves as a ‘hall of fame’ for executives who have been recognized multiple times in the PharmaVOICE 100, the publication’s annual list of inspiring industry leaders. PharmaVOICE 100 Red Jacket Award winners are selected as individuals who have shown a new kind of leadership, such as driving new ways of thinking, acting and leading; creating new opportunities from the ‘impossible’; having persistence of vision; and inspiring leaders for today and tomorrow.
“I am honored and grateful to be inducted into such an influential circle of leaders as the PharmaVOICE 100 Red Jacket Award,” said Dr. Durrant. “Finding new ways forward requires the persistence and resilience to execute and deliver them. This honor reflects the determination and forward-thinking mindset of our talented team at Humanigen, as we continue to execute on our priorities to help neglected and rare disease patients.”
Since January 2016, Dr. Durrant has led the transformation of Humanigen through significant operational, reputational and legal hurdles. Dr. Durrant is a five-time PharmaVOICE 100 honoree. To read the 2017 PharmaVOICE 100 Red Jacket Award profiles, visit www.pharmavoice.com.
About Humanigen
Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit www.humanigen.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
